| Dr Carl Eugene Miller Jr, DPM | |
|
521 E Main St, Jenks, OK 74037-4136 | |
| (918) 584-8880 | |
| (918) 584-8881 |
| Full Name | Dr Carl Eugene Miller Jr |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 17 Years |
| Location | 521 E Main St, Jenks, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194991828 | NPI | - | NPPES |
| 200724730A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 277 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tulsa Podiatry Clinics Llc | 5395008601 | 3 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago
| Provider Name | Ahs Oklahoma Physician Group Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1235182775 PECOS PAC ID: 9436122496 Enrollment ID: O20040817001197 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago
| Provider Name | Creek Nation Hospital & Clinics |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago
| Provider Name | Newstep Plc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588184014 PECOS PAC ID: 2264791532 Enrollment ID: O20180116000450 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago
| Provider Name | Tulsa Podiatry Clinics Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1619475696 PECOS PAC ID: 5395008601 Enrollment ID: O20180420000161 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Carl Eugene Miller Jr, DPM 521 E Main St, Jenks, OK 74037-4136 Ph: (918) 584-8880 | Dr Carl Eugene Miller Jr, DPM 521 E Main St, Jenks, OK 74037-4136 Ph: (918) 584-8880 |
News Archive
Low oxygen levels are a well-known cause of brain injury in premature babies. But the mechanism by which low oxygen hurts the developing human brain has been unclear.
News coverage is focusing on the notion that a large percentage of people who currently have individual health coverage are receiving cancellation notices because their plans don't meet the standards created by the health law. Many of these people, according to reports, will face "sticker shock" with their new insurance. A critical emerging question is whether the Obama administration expected this scenario.
Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.
TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.
› Verified 8 days ago